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Objective: To provide a management approach for adults with calcium channel blocker poisoning.
Data Sources, Study Selection, and Data Extraction: Following the
Appraisal of Guidelines for Research & Evaluation II instrument,
initial voting statements were constructed based on summaries
outlining the evidence, risks, and benefits.
Data Synthesis: We recommend 1) for asymptomatic patients, observation and consideration of decontamination following a potentially
toxic calcium channel blocker ingestion (1D); 2) as first-line therapies
(prioritized based on desired effect), IV calcium (1D), high-dose insulin
therapy (1D–2D), and norepinephrine and/or epinephrine (1D). We
also suggest dobutamine or epinephrine in the presence of cardiogenic shock (2D) and atropine in the presence of symptomatic bradycardia or conduction disturbance (2D); 3) in patients refractory to the
first-line treatments, we suggest incremental doses of high-dose insulin therapy if myocardial dysfunction is present (2D), IV lipid-emulsion
therapy (2D), and using a pacemaker in the presence of unstable bradycardia or high-grade arteriovenous block without significant alteration in cardiac inotropism (2D); 4) in patients with refractory shock or
who are periarrest, we recommend incremental doses of high-dose
insulin (1D) and IV lipid-emulsion therapy (1D) if not already tried. We
suggest venoarterial extracorporeal membrane oxygenation, if available, when refractory shock has a significant cardiogenic component
(2D), and using pacemaker in the presence of unstable bradycardia
or high-grade arteriovenous block in the absence of myocardial dysfunction (2D) if not already tried; 5) in patients with cardiac arrest, we
recommend IV calcium in addition to the standard advanced cardiac
life-support (1D), lipid-emulsion therapy (1D), and we suggest venoarterial extracorporeal membrane oxygenation if available (2D).
Conclusion: We offer recommendations for the stepwise management of calcium channel blocker toxicity. For all interventions, the level
of evidence was very low. (Crit Care Med 2017; 45:e306–e315)
Key Words: antidotes; calcium channel blockers; cardiotoxicity;
drug overdose; therapy; toxicity

T

oxicity from cardiac drugs is associated with a large
number of fatalities and significant morbidity (1, 2).
Furthermore, the advice given by poison control centers
are often not followed (2–4). Consensus recommendations
were published for out-of-hospital management of calcium
channel blocker (CCB) ingestion (5), but recommendations
for in-hospital care have not been systematically developed.
In the absence of formally recognized guidelines, we convened
a workgroup of experts involved in the care of poisoned patients
to develop evidence-based recommendations to guide the in-hospital management of CCB poisoning. Considering the very low
level of evidence found in the literature, the workgroup agreed
on developing expert consensus recommendations to propose a
management approach and facilitate knowledge translation. In
light of the variable pharmacokinetics among the available CCBs
(6, 7), the altered pharmacokinetics following overdose (8, 9)
and the loss of selectivity at very high CCB doses (10, 11), the
workgroup adopted a pragmatic clinical approach and did not
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focus on individual agents (for complementary information concerning CCB poisoning, see Appendix 1, Supplemental Digital
Content 1, http://links.lww.com/CCM/C94).

MATERIALS AND METHODS
Objective, Scope, Target Users, and Analytical
Framework
These recommendations aimed to improve the management of
CCB-poisoning and address which types of in-hospital interventions should be considered for adults with a potentially
toxic ingestion of CCB. In addition to these recommendations, the workgroup would also like to emphasize the possible
important role of poison centers. The workgroup (Table 1)
was created as detailed in Appendix 2 (Supplemental Digital
Content 1, http://links.lww.com/CCM/C94), and an analytical
framework illustrating the links between key questions (KQ) to
be answered (Fig. 1) was developed (12).
The Appraisal of Guidelines for Research & Evaluation II
instrument (13) provided the basis for the development of
these recommendations and for the review process. The level of
evidence was determined using Grading of Recommendations
Assessment, Development and Evaluation (14) and the
strength of recommendation using a modified Delphi like it
has been used in consensus recommendations for extracorporeal treatments (Table 2) (Appendix 2, Supplemental Digital
Content 1, http://links.lww.com/CCM/C94) (Fig. 2).

RESULTS
Table 2 defines the wording used for the recommendations.
Supplemental Table 1 (Supplemental Digital Content 2,
http://links.lww.com/CCM/C95) (also, see Appendix 6, Supplemental Digital Content 1, http://links.lww.com/CCM/C94)
details the rationale for each recommendation, and Figure 3
illustrates the progression of care for key recommendations.

RECOMMENDATIONS
Therapy in Asymptomatic Patients
For the treatment of patients who ingested a potentially toxic
amount of CCB, the workgroup recommends observation and
consideration of decontamination following the position statements previously published jointly by the European Association
of Poison Centres and Clinical Toxicologists (EAPCCT) and the
American Academy of Clinical Toxicology (AACT) (16) (1D):
“Based on volunteer studies, the administration of activated
charcoal may be considered if a patient has ingested a potentially
toxic amount of a poison (…) up to one hour previously. (…) the
potential for benefit after one hour cannot be excluded.”
Rationale
Based on case series (17–19), it is preferable to observe and
monitor in a hospital setting for approximately 24 hours
asymptomatic patients who ingested a potentially toxic
amount of CCB, defined as more than a single therapeutic dose (5), to consider gastrointestinal decontamination
www.ccmjournal.org
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TABLE 1.

Participating Organizations

Name

Organization (One Vote/Organization)

Expertise

Frank Lee Cantrell, United
States

American Association of Poison Control Centres

Pharmacist

Eric Lavonas and William
Kerns II, United States

American College of Medical Toxicology

Emergency physicians, medical toxicologists

Sophie Gosselin, Canada

Canadian Association of Emergency Physicians

Emergency physician, medical toxicologist

Martin Laliberté, Canada

Canadian Association of Poison Control Centres

Emergency physician, medical toxicologist

John Muscedere and
Tasnim Sinuff, Canada

Canadian Critical Care Society

Critical care physicians, internists

Michael Rieder and Benoit
Bailey (co-chair), Canada

Canadian Paediatric Society

Pediatricians (M.R. and B.B.), clinical
pharmacologist (M.R.) and medical
toxicologist (B.B.)

Philippe Hantson, Belgium

European Association of Poison Centres and
Clinical Toxicologists

Critical care physician, medical toxicologist

Kurt Anseeuw, Belgium

European Society of Emergency Medicine

Emergency physician, anesthesiologist, medical
toxicologist

Bruno Mégarbane, France

European Society of Intensive Care Medicine

Critical care physician, medical toxicologist

Ian Gilchrist, United States

Society of Critical Care Medicine

Critical care physician, cardiologist

Canadian Association of Poison Control Centres

Consensus Review Chair, emergency physician,
critical care physician, medical toxicologist

Voting members

Nonvoting members
Maude St-Onge, Canada
David Juurlink

Epidemiologist, methodologist

Valéry Lavergne

Epidemiologist, methodologist

N.B.: A public health and medical toxicologist from Taiwan, and another medical toxicologist from United States also participated to the vote.

Figure 1. Analytical framework for calcium channel blocker (CCB) poisoning treatment guidelines. Key questions (KQ): 1) Is there direct evidence that
one (or more than one) intervention reduces mortality (critical outcome), improves functional outcomes, reduces hospital length of stay (LOS) or reduces
ICU LOS (important outcomes)? 2) Does the patient clinical presentation or type of ingestion influence the intervention(s) provided and the outcomes?
3) Does one (or more than one) intervention decrease CCB serum concentration, improve hemodynamics, or reduce the duration of vasopressor use? 4)
Are the intermediate outcomes reliably associated with reduced mortality or improved functional outcomes? 5) Does one (or more than one) intervention
result in adverse effects or demonstrate a lack of cost-effectiveness?
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TABLE 2.

Levels of Evidence and Strength of Recommendation

Strengths of recommendation
Level 1: Strong recommendation (appropriate by the large majority of experts with no major dissension). The desirable effects of
adherence to the recommendation outweigh the undesirable effects.
   In favor: “we recommend”
   Against: “we recommend not to”
Level 2: Weak recommendation (appropriate by the majority of experts, but some degree of dissension exists). The desirable
effects of adherence to the recommendation probably outweigh the undesirable effects.
   In favor: “we suggest”
   Against: “we suggest not to”
Level 3: Neutral recommendation. The course of action could be considered appropriate in the right context.
Levels of evidence
Grade A: High level of evidence. We are confident that the true effect is close to our estimate of the effect.
Grade B: Moderate level of evidence. The true effect is likely to be close to our estimate of the effect, but there is a possibility
that it is substantially different.
Grade C: Low level of evidence. The true effect may be substantially different from our estimate of the effect.
Grade D: Very low level of evidence. Our estimate of the effect is just a guess, and it is very likely that the true effect is
substantially different from our estimate of the effect.

(20–22) and to intervene with other treatments if signs of
toxicity develop. The workgroup deferred the indications for,
and types of, decontamination to the AACT and the EAPCCT
position statement (2005) (16) instead of proposing new
recommendations.
First-Line Therapy for Symptomatic Patients
For first-line therapy of symptomatic CCB-poisoned patients,
the workgroup recommends the use of
●●
●●

●●

IV calcium (1D)
High-dose insulin therapy with other first line treatment(s)
if evidence of myocardial dysfunction is present (1D),
Norepinephrine and/or epinephrine in the presence
of shock (even if myocardial function has not yet been
assessed), with preferential use of norepinephrine in the
presence of vasodilatory shock (1D).

For the first-line therapy of symptomatic CCB-poisoned
patients, the workgroup suggests the use of
●●

●●

●●

●●

High-dose insulin therapy as a monotherapy in the presence of myocardial dysfunction (2D),
High-dose insulin therapy in the absence of documented
myocardial dysfunction if used in combination with IV fluids, calcium, and vasopressors (2D),
Dobutamine or epinephrine in the presence of cardiogenic
shock (2D),
Atropine in the presence of symptomatic bradycardia or
conduction disturbances (2D).

For the first-line therapy of symptomatic CCB-poisoned
patients, the workgroup suggests not to use
●●

Dopamine in the presence of shock (2D),

Critical Care Medicine

●●

Vasopressin as a single vasoactive agent in the presence of
documented cardiogenic shock (2D).

Rationale
The workgroup agreed that each of the treatments here mentioned could be considered as first line alone or in combination.
A supplementary round of Delphi did not allow prioritization
of one intervention over another. Comparative studies were
rare, and more than one interventions were done concurrently
in most of the studies reviewed. Therefore, the workgroup
emphasized that the first-line treatments should be prioritized
based on the desired effect tailored to the individual patient’s
clinical condition (Fig. 3; Supplemental Table 1, Supplemental
Digital Content 2, http://links.lww.com/CCM/C95).
The workgroup recommended IV calcium as a first-line
treatment based on improvement in contractility and blood
pressure observed in some case series (23–26) and animal studies (27–33). This therapy is readily available and carries little
risk provided central venous or secure peripheral venous access
is available. The regimen often used for the administration of
10% calcium chloride in CCB-poisoned adults is 10–20 mL
(1–2 g) every 10–20 minutes or an infusion at 0.2–0.4 mL/kg/
hr (0.02–0.04 g/kg/hr). When 10% calcium gluconate is given,
notably to minimize peripheral vein irritation, the dose regimen frequently used is 30–60 mL (3–6 g) every 10–20 minutes
or an infusion at 0.6–1.2 mL/kg/hr (0.06–0.12 g/kg/hr) (23).
Observational studies (34, 35), case series (4, 36–38), and
animal studies (39–42) document an improvement in contractility, blood pressure, and a potential increase in survival
with the use of high-dose insulin in CCB-poisoned patients.
Considering that high-dose insulin seems to have a direct
www.ccmjournal.org
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Figure 2. Voting process for recommendations.

positive inotropic effect (39, 42), the workgroup recommended
its use in the face of documented myocardial dysfunction, but
still suggested if myocardial dysfunction is not documented

because case series documented
hemodynamic
improvement
even with dihydropyridines
poisoning (19). Despite the fact
that high-dose insulin requires
intensive monitoring, its benefits were thought to outweigh
the risks such as hypoglycemia,
hypokalemia, or volume overload (4). The proposed dose
regimen of high-dose insulin (regular insulin) includes
a bolus of 1 U/kg followed by
an infusion of 1 U/kg/hr with
maintenance of euglycemia with
a dextrose infusion as needed
and close monitoring of serum
potassium. Because titration of
high-dose insulin to response
up to 10 U/kg/hr is supported only by case series, the workgroup suggests to use this dosage only for patients who do not
respond to first-line therapies (43).

Figure 3. Progression of care for key recommendations. ACLS = advanced cardiac life-support, CCB = calcium channel blocker, ECLS = Extracorporeal
Life Support, VA-ECMO = venoarterial extracorporeal membrane oxygenation.
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The selection of vasopressors should be guided by the type
of shock. Based on mechanism of action, the workgroup recommended the use of norepinephrine to increase blood pressure in vasoplegic shock or if myocardial function has not yet
been assessed (30, 32, 44). The use of epinephrine is also recommended for a CCB-poisoned patient in shock to increase
contractility and heart rate (30, 32, 39). In the presence of confirmed myocardial dysfunction, clinicians can also use dobutamine (44). High infusion rates of vasopressors and inotropes
may be required (44).
Based on inconsistent hemodynamic improvement in case
series (23–25), the workgroup suggest not to use dopamine. The
use of vasopressin alone was discouraged due to lack of efficacy
and worsened survival in animal models (45, 46). The workgroup could not make recommendations regarding the use of
vasopressin as an adjunct to other vasopressors as there is little
documented clinical experience. No agreement was reached for
the use of phenylephrine in CCB-poisoned patients.
In situations in which there is symptomatic bradycardia or
conduction disturbances, the workgroup suggested using atropine at a dose regimen of 0.5 mg every 3–5 minutes for few
doses if needed. This suggestion is supported based on considerations that the therapy may temporarily help, is easily accessible, is inexpensive, and is associated with few risks (30, 32).
Although fluid resuscitation is commonly used, no formal
recommendation was made because no fluid repletion studies were found specifically for CCB poisoning. Nonetheless,
the workgroup considered fluid administration as a first-line
therapy and continued administration as long as the patient
demonstrates evidence of fluid responsiveness (e.g., hemodynamic improvement based on hemodynamic parameters and
monitoring devices such as echocardiography after receiving
10–20 mL/kg of crystalloid over 10–15 min).

associated with frequent capture and pacing problems. However, there may be hemodynamic improvement in patients
presenting with unstable bradycardia or high-grade AV block
(47–50). To avoid spending time on a therapy that involves risk
and may not be effective, the workgroup suggested to attempt
transcutaneous pacing first. If transcutaneous pacing is effective, IV pacing can be instituted when clinically appropriate.
Based on possible hemodynamic improvement documented in
animal studies (51–53), case series (54, 55) and case reports (56,
57), the workgroup also suggested the use of lipid-emulsion therapy. However, this is not recommended earlier in therapy in the
absence of cardiac arrest, given the inconsistent response and the
concern of potentially increasing the absorption of medications
still present in the gastrointestinal tract by changing the distribution of the CCB. This concern was reported in an animal study
only published as an abstract at the time of analysis showing worse
outcomes (58) with an oral model of CCB poisoning. The workgroup felt that there were insufficient data to recommend a specific
dose regimen of lipid-emulsion therapy. The dose most commonly
used is 1.5 mL/kg of 20% lipid emulsion administered as a bolus,
repeated up to twice as needed until clinical stability is achieved,
and followed by an infusion of 0.25 mL/kg/min for 30–60 minutes
(59). The Food and Drug Administration fixed a maximum total
dose administered per 24 hour of 12.5 mL/kg (60).

Therapy for Patients Refractory to First-Line
Treatments
For the therapy of CCB-poisoned patients refractory to firstline treatments, the workgroup suggests the use of

For the therapy of CCB-poisoned patients in refractory
shock or periarrest, the workgroup suggests, as rescue treatments, the use of

●●

●●

●●

Incremental doses of high-dose insulin therapy (up to
10 U/kg/hr) if evidence of myocardial dysfunction is
present (2D),
Pacemaker in the presence of unstable bradycardia or highgrade AV block, without significant alteration in cardiac
inotropism (2D),
IV lipid-emulsion therapy (2D).

Rationale
In patients refractory to the first-line treatments, the workgroup considered therapies supported by a limited number of
case series and associated with a moderate risk. The workgroup
kept therapies associated with higher risks for rescue treatments. Therefore, in the presence of myocardial dysfunction,
the workgroup suggested to titrate high-dose insulin infusion
rates up to 10 U/kg/hr to improve inotropy and facilitates the
use of carbohydrates by the myocardium (43) with a dextrose
infusion to maintain euglycemia if needed. Pacing has been
Critical Care Medicine

Therapy for Patients in Refractory Shock or Periarrest
For the therapy of CCB-poisoned patients in refractory shock or
periarrest despite increasing doses of inotropes and vasopressors,
the workgroup recommends the following as rescue treatments:
●●

●●

●●

●●

●●

Incremental doses of high-dose insulin therapy (up to 10
U/kg/hr) if evidence of myocardial dysfunction is present if
not administered previously (1D),
Lipid-emulsion therapy if not administered previously (1D)

Incremental doses of high-dose insulin therapy (up to 10 U/
kg/hr) even in the absence of myocardial dysfunction if not
administered previously (2D),
VA-ECMO in presence of cardiogenic shock in centers
where the treatment is available (2D),
Pacemaker in the presence of unstable bradycardia or highgrade AV block, without significant alteration in cardiac
inotropy if not tried previously (2D).

Rationale
Given the high risk of mortality in patients with severe refractory
shock or periarrest, the workgroup members considered therapies
with less evidence and/or greater risks. Therefore, incremental
doses of high-dose insulin therapy are suggested even if no myocardial dysfunction has been documented (43) and the use of lipidemulsion therapy is recommended in that situation (52,53,55–57).
Given the risk of mortality in severely poisoned patients
and the potential survival benefit demonstrated in an
observational study conducted in experienced centers (61),
www.ccmjournal.org

Copyright © 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

e311

St-Onge et al

the workgroup members suggested venoarterial extracorporeal membrane oxygenation (VA-ECMO), which allows
gas exchange and hemodynamic support, while blood is
pumped from the venous to the arterial side, as a rescue
therapy in CCB-poisoned patients presenting with cardiogenic shock or mixed shock involving a significant cardiogenic part in centers where the treatment is available. In
this clinical scenario, the workgroup concluded that the
benefits outweigh the risks of limb ischemia, bleeding,
or thrombosis. The members were neutral with regard to
the use of the Impella catheter (Abiomed, Danvers, MA)
or other ventricular-assisted devices as potential alternatives to VA-ECMO as there is simply insufficient clinical or
research experience (62).

TABLE 3. Participating Organizations That
Endorsed the Recommendations After
an Internal Review Process Based on the
AGREE II Instrument
American Association of Poison Control Centres
American College of Medical Toxicology
Canadian Association of Emergency Physiciansa
Canadian Association of Poison Control Centres
Canadian Critical Care Society
Canadian Paediatric Society
European Association of Poison Centres and Clinical
Toxicologists

Therapy for Patients in Cardiac Arrest
For therapy of CCB-poisoned patients in cardiac arrest, the
workgroup recommends, in addition to standard advanced cardiac life-support provided to nonpoisoned patients, the use of
●●
●●

IV calcium, even if previously administered (1D),
Lipid-emulsion therapy if not administered previously (1D).

For therapy of CCB-poisoned patients in cardiac arrest, the
workgroup suggests the use of
●●
●●

Lipid-emulsion therapy, even if previously administered (2D),
VA-ECMO in centers where the treatment is available (2D).

Rationale
Studies looking specifically at CCB-poisoned patients in cardiac
arrest are scarce. Most recommendations other than use of VAECMO are extrapolated from studies conducted in severely ill
patients not in cardiac arrest. Therefore, the workgroup emphasized the importance of aggressive resuscitation with the previously mentioned modalities. Consequently, the workgroup
members recommended the use of IV calcium and lipid-emulsion therapy at the same dose regimen described earlier. Furthermore, a second dose of lipid-emulsion therapy overall is
suggested even if the patient already received a bolus before the
cardiac arrest.
Concerning the use of VA-ECMO in experienced centers,
observational studies and case reports have demonstrated
a survival benefit in cardiac arrest patients (61, 63–67). The
workgroup members estimated that the benefit of saving a life
outweighs the risks of initiating such invasive therapy as long
as there is a reasonable chance of surviving without significant
deficit. The workgroup recognized that a long period of low
flow may be associated with poorer outcomes, but the evidence
is unclear regarding the time to declare futility.
The rationale for not recommending or suggesting other
treatments such as glucagon or methylene blue is available
in Appendix 7 (Supplemental Digital Content 1, http://links.
lww.com/CCM/C94). A description of values and preferences,
the result of the review process, and the planned implementation and revisions are available in Appendix 2 (Supplemental
Digital Content 1, http://links.lww.com/CCM/C94).
e312
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European Society of Emergency Medicine
European Society of Intensive Care Medicine
Society of Critical Care Medicine
Endorsed the submitted article to Critical Care Medicine and will review the
accepted article.

a

DISCUSSION
The target population for these recommendations includes
CCB-poisoned adults. However, given the paucity of literature
for the treatment of CCB-poisoned children and the absence
of evidence that children respond differently than adults to
CCB poisoning, the workgroup believes that it is reasonable to
apply the recommendations to the pediatric population.
Even if articles were found to answer some KQs (1–5),
the overall evidence available to develop these recommendations was of very low quality. Many interventions had only
been studied for surrogate outcomes. With the exception of
VA-ECMO for cardiotoxicant poisonings, the use of and costs
associated with these resources had not been described (KQ5)
(Fig. 1) (68). Hence, many questions within our proposed analytic framework remain unanswered (Fig. 1). These represent
potential areas for future research.
First, comparative studies should be conducted to identify
which intervention improves intermediate and health outcome
(KQ 1, 3, and 4) for each specific class of CCB (KQ 2) with
acceptable adverse effects and cost (KQ 5). Second, observational studies should identify prognostic factors, which is particularly imperative in severe cases that may potentially require
VA-ECMO (KQ 2). Third, scientists should conduct clinical
trials to identify factors associated with favorable responses
to high-dose insulin therapies (KQ 2). Prospective, controlled
clinical trials are needed to evaluate currently recommended
antidotes or to assess new ones (KQ 1, 3, 4, and 5) (Table 3).

CONCLUSION
Those recommendations have been developed to help improve
current treatment of CCB-poisoned patients by reducing physician practice variation. The workgroup also identified potential areas for future research.
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